The online reference source for the interventional NeuroRadiology, Neurology and NeuroSurgery community
Wallaby Medical announces CE Mark approval and FDA 510(k) clearance of its differentiated embolic coil system, the Avenir Coil System. The intended use for the Avenir Coil System is for endovascular embolization of intracranial aneurysms and other neurovascular abnormalities such as arteriovenous malformations and arteriovenous fistulae. The Avenir Coil System is also intended for arterial and venous embolization in the peripheral vasculature.
September 17, 2019
Watch this clinical case report from a 75 year old female patient presented with NIHSS of 19 presented 4 hours after symptom onset.It was noted that the patient had had a knee implant surgery 3 days prior to her stroke. Additional risk factors included: Coronary Heart Failure, Hypertension, Diabetes, Atrial fibrillation.On admission CT ASPECTS was 10.Imaging confirmed distal left MCA occlusion.
July 31, 2019
DUBLIN and SAN FRANCISCO, July 22, 2019 (GLOBE NEWSWIRE) - Medtronic plc (NYSE:MDT), a global leader in medical technology, and Viz.ai, the emerging leader in applied artificial intelligence (AI) in stroke care, have partnered to accelerate the adoption of Viz.ai’s new technology, which helps synchronize stroke care and decrease time to treatment, potentially improving outcomes for patients.
July 22, 2019
Nashville, TN, May 22, 2019 Vesalio announces it has obtained its second CE Approval spanning multiple new NeVa™ product designs and technology. The new generation NeVa devices expand on the Drop Zone™ and Smart Marker™ technologies while also introducing first to market features such as a distal filter. A controlled launch of the new technology will begin in June in Europe with expected full commercial release in Q4 of this year.
May 22, 2019
Nashville, TN, May 14, 2019 Vesalio announces it has recently raised $5 million in funding. The capital will support the continued global expansion of the NeVa™ Neurothrombectomy System, finance key clinical studies and launch new product introductions.
May 15, 2019
IRVINE, Calif.-- (BUSINESS WIRE )-- Balt USA, LLC announces today it has obtained CE mark for the Titan aspiration catheter. The Titan catheter line consists of a highly navigable, large bore (.070”) aspiration catheter and a smaller bore (.036”) catheter for navigation and support. Obtaining the CE mark for Titan* enhances the Balt stroke portfolio as it will be available alongside the CatchView* revascularization stent, Vasco* catheters, Ballast long sheath and Hybrid guidewires to provide a complete stroke solution to the marketplace.
May 14, 2019
The WEB-IT pivotal trial highlights positive clinical outcomes with the WEB® Aneurysm Embolization System, the only intrasaccular flow disruptor approved in the United States.
April 18, 2019
Pascal Girin, CEO of BALT, shares how his rich career in neurovascular medical technology helped him to transform the company from a small R&D pure player into an international market leader. Girin goes on to explain the high key growth strategy he is implementing and the impact that BALT’s products can have on the quickly developing medical field of stroke treatment.
April 11, 2019
Nashville, TN, April 02, 2019 --(PR.com)-- Vesalio announces it has executed multiple exclusive distribution agreements in Europe, Latin America, Asia and the Middle East and now has market coverage in 39 countries for the NeVa™ Neuro-thrombectomy System.
April 8, 2019
Balt International has announced receiving the CE mark for the Ballast .088 Long Sheath. The Ballast .088 Long sheath is indicated for the introduction of interventional devices into peripheral, coronary and neurovasculature. It is a class III medical device which is described as a guiding catheter and as an introducer sheath.The Ballast .088 will be commercially available in different lengths, from 80 cm, via 90 cm and up to a 100 cm long.This new generation sheath is designed with a braided reinforced proximal segment, an optimised progressively softer distal coil segment and a low-profile outer diameter to deliver the right balance between atraumatic navigation and proximal support.With this new Ballast .088 Long sheath, Balt International offers its premium sheath, designed to improve support and navigationPascal Girin, Balt International’s CEO stated, "The clearance of the Ballast .088 Long Sheath is a significant milestone in our global commercialisation efforts and a major step towards delivering a complete portfolio of innovative solutions"."The Ballast .088 Long Sheath represents an advance in technology for physicians around the world. It also is a fantastic representation of the capabilities of the new global Balt, with full R&D teams in both France and the USA developing physician inspired technologies to advance the care of patients with neurovascular diseases" commented Dave Ferrera, Senior VP of Global R&D and CTO of Balt USA.
March 23, 2019